Central obesity, hepatic lipase activity and dyslipidemia in type 1 diabetes

S. D. Sibley, J. E. Hokanson, Jonathan Purnell, J. P. Palmer, I. B. Hirsch, J. D. Brunzell

Research output: Contribution to journalArticle

Abstract

Excessive weight-gain in a subset of the intensively treated cohort of the Diabetes Control and Complications Trial (DCCT) was associated with insulin resistance, high waist-to-hip ratio and blood pressure, and an atherogenic dyslipidemia with elevations in triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (apoB) in the presence of small-dense LDL, and decreased high-density lipoprotein subclass 2 cholesterol (HDL2-C) suggesting that intensive therapy unmasked the central obesity syndrome in some insulin resistant subjects. In studies of subjects who do not have type 1 diabetes, higher intraabdominal fat (IAF) is associated with higher hepatic lipase activity (HL) and high HL is associated with a similar atherogenic dyslipidemia. The purpose of this study was to investigate the relationship between IAF, HL, and dyslipidemia in subjects with type 1 diabetes. Twenty-one subjects from the Seattle cohort of the Epidemiology of Diabetes Intervention and Complications Trial (EDIC) (15 males and 6 females) have completed baseline IAF (via CT at the umbilicus), HL, standard serum lipids, and lipoprotein measures. In these subjects, a significant positive relationship exists between IAF and HL (r=0.597, p=0.004), A significant positive relationship exists between IAF and log TG (r=0.726, p2-C (r=0.570, p=0.007). HL was positively related to apoB (r=0.613, p=0.009) and LDL-Rf (r=0.776, p2-C (r=0.510, p=0.018). When HDL2-C is adjusted for HL, it is no longer significantly related to IAF. These data suggest that in an unselected group of subjects with type 1 diabetes, increased IAF is strongly and directly related to increased HL which may be a mediator of the dyslipidemia.

Original languageEnglish (US)
JournalJournal of Investigative Medicine
Volume47
Issue number2
StatePublished - Feb 1999
Externally publishedYes

Fingerprint

Abdominal Obesity
Medical problems
Dyslipidemias
Lipase
Type 1 Diabetes Mellitus
Fats
Liver
HDL2 Lipoprotein
Apolipoproteins B
Diabetes Complications
Triglycerides
Cholesterol
Insulin
Umbilicus
Epidemiology
Waist-Hip Ratio
Blood pressure
LDL Cholesterol
Lipoproteins
Weight Gain

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Sibley, S. D., Hokanson, J. E., Purnell, J., Palmer, J. P., Hirsch, I. B., & Brunzell, J. D. (1999). Central obesity, hepatic lipase activity and dyslipidemia in type 1 diabetes. Journal of Investigative Medicine, 47(2).

Central obesity, hepatic lipase activity and dyslipidemia in type 1 diabetes. / Sibley, S. D.; Hokanson, J. E.; Purnell, Jonathan; Palmer, J. P.; Hirsch, I. B.; Brunzell, J. D.

In: Journal of Investigative Medicine, Vol. 47, No. 2, 02.1999.

Research output: Contribution to journalArticle

Sibley, SD, Hokanson, JE, Purnell, J, Palmer, JP, Hirsch, IB & Brunzell, JD 1999, 'Central obesity, hepatic lipase activity and dyslipidemia in type 1 diabetes', Journal of Investigative Medicine, vol. 47, no. 2.
Sibley, S. D. ; Hokanson, J. E. ; Purnell, Jonathan ; Palmer, J. P. ; Hirsch, I. B. ; Brunzell, J. D. / Central obesity, hepatic lipase activity and dyslipidemia in type 1 diabetes. In: Journal of Investigative Medicine. 1999 ; Vol. 47, No. 2.
@article{da63e11c819d452b980db986e42b4291,
title = "Central obesity, hepatic lipase activity and dyslipidemia in type 1 diabetes",
abstract = "Excessive weight-gain in a subset of the intensively treated cohort of the Diabetes Control and Complications Trial (DCCT) was associated with insulin resistance, high waist-to-hip ratio and blood pressure, and an atherogenic dyslipidemia with elevations in triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (apoB) in the presence of small-dense LDL, and decreased high-density lipoprotein subclass 2 cholesterol (HDL2-C) suggesting that intensive therapy unmasked the central obesity syndrome in some insulin resistant subjects. In studies of subjects who do not have type 1 diabetes, higher intraabdominal fat (IAF) is associated with higher hepatic lipase activity (HL) and high HL is associated with a similar atherogenic dyslipidemia. The purpose of this study was to investigate the relationship between IAF, HL, and dyslipidemia in subjects with type 1 diabetes. Twenty-one subjects from the Seattle cohort of the Epidemiology of Diabetes Intervention and Complications Trial (EDIC) (15 males and 6 females) have completed baseline IAF (via CT at the umbilicus), HL, standard serum lipids, and lipoprotein measures. In these subjects, a significant positive relationship exists between IAF and HL (r=0.597, p=0.004), A significant positive relationship exists between IAF and log TG (r=0.726, p2-C (r=0.570, p=0.007). HL was positively related to apoB (r=0.613, p=0.009) and LDL-Rf (r=0.776, p2-C (r=0.510, p=0.018). When HDL2-C is adjusted for HL, it is no longer significantly related to IAF. These data suggest that in an unselected group of subjects with type 1 diabetes, increased IAF is strongly and directly related to increased HL which may be a mediator of the dyslipidemia.",
author = "Sibley, {S. D.} and Hokanson, {J. E.} and Jonathan Purnell and Palmer, {J. P.} and Hirsch, {I. B.} and Brunzell, {J. D.}",
year = "1999",
month = "2",
language = "English (US)",
volume = "47",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Central obesity, hepatic lipase activity and dyslipidemia in type 1 diabetes

AU - Sibley, S. D.

AU - Hokanson, J. E.

AU - Purnell, Jonathan

AU - Palmer, J. P.

AU - Hirsch, I. B.

AU - Brunzell, J. D.

PY - 1999/2

Y1 - 1999/2

N2 - Excessive weight-gain in a subset of the intensively treated cohort of the Diabetes Control and Complications Trial (DCCT) was associated with insulin resistance, high waist-to-hip ratio and blood pressure, and an atherogenic dyslipidemia with elevations in triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (apoB) in the presence of small-dense LDL, and decreased high-density lipoprotein subclass 2 cholesterol (HDL2-C) suggesting that intensive therapy unmasked the central obesity syndrome in some insulin resistant subjects. In studies of subjects who do not have type 1 diabetes, higher intraabdominal fat (IAF) is associated with higher hepatic lipase activity (HL) and high HL is associated with a similar atherogenic dyslipidemia. The purpose of this study was to investigate the relationship between IAF, HL, and dyslipidemia in subjects with type 1 diabetes. Twenty-one subjects from the Seattle cohort of the Epidemiology of Diabetes Intervention and Complications Trial (EDIC) (15 males and 6 females) have completed baseline IAF (via CT at the umbilicus), HL, standard serum lipids, and lipoprotein measures. In these subjects, a significant positive relationship exists between IAF and HL (r=0.597, p=0.004), A significant positive relationship exists between IAF and log TG (r=0.726, p2-C (r=0.570, p=0.007). HL was positively related to apoB (r=0.613, p=0.009) and LDL-Rf (r=0.776, p2-C (r=0.510, p=0.018). When HDL2-C is adjusted for HL, it is no longer significantly related to IAF. These data suggest that in an unselected group of subjects with type 1 diabetes, increased IAF is strongly and directly related to increased HL which may be a mediator of the dyslipidemia.

AB - Excessive weight-gain in a subset of the intensively treated cohort of the Diabetes Control and Complications Trial (DCCT) was associated with insulin resistance, high waist-to-hip ratio and blood pressure, and an atherogenic dyslipidemia with elevations in triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (apoB) in the presence of small-dense LDL, and decreased high-density lipoprotein subclass 2 cholesterol (HDL2-C) suggesting that intensive therapy unmasked the central obesity syndrome in some insulin resistant subjects. In studies of subjects who do not have type 1 diabetes, higher intraabdominal fat (IAF) is associated with higher hepatic lipase activity (HL) and high HL is associated with a similar atherogenic dyslipidemia. The purpose of this study was to investigate the relationship between IAF, HL, and dyslipidemia in subjects with type 1 diabetes. Twenty-one subjects from the Seattle cohort of the Epidemiology of Diabetes Intervention and Complications Trial (EDIC) (15 males and 6 females) have completed baseline IAF (via CT at the umbilicus), HL, standard serum lipids, and lipoprotein measures. In these subjects, a significant positive relationship exists between IAF and HL (r=0.597, p=0.004), A significant positive relationship exists between IAF and log TG (r=0.726, p2-C (r=0.570, p=0.007). HL was positively related to apoB (r=0.613, p=0.009) and LDL-Rf (r=0.776, p2-C (r=0.510, p=0.018). When HDL2-C is adjusted for HL, it is no longer significantly related to IAF. These data suggest that in an unselected group of subjects with type 1 diabetes, increased IAF is strongly and directly related to increased HL which may be a mediator of the dyslipidemia.

UR - http://www.scopus.com/inward/record.url?scp=33750140953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750140953&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33750140953

VL - 47

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 2

ER -